Research programme: vascular diseases - CollaGenex/Medtronic

Drug Profile

Research programme: vascular diseases - CollaGenex/Medtronic

Latest Information Update: 19 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CollaGenex Pharmaceuticals
  • Developer CollaGenex Pharmaceuticals; Medtronic
  • Class Tetracyclines
  • Mechanism of Action Cytokine inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Vascular disorders

Most Recent Events

  • 19 Apr 2010 Discontinued - Preclinical for Vascular disorders in USA (Implant)
  • 11 Apr 2008 CollaGenex Pharmaceuticals has been acquired by Galderma
  • 04 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top